|
시장보고서
상품코드
2076006
기저 인슐린 시장 : 유형별, 투여 장비별, 적응증별, 연령층별, 유통 채널별, 지역별Basal Insulin Market, By Type, By Delivery Device, By Indication, By Age Group, By Distribution Channel, By Geography |
||||||
기저 인슐린 시장은 2026년에 216억 2,000만 달러 규모에 이를 것으로 추정되고 있어 2033년까지 421억 2,000만 달러에 이를 것으로 예상되고 있습니다. 2026년부터 2033년까지 CAGR 10.0%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 216억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간 CAGR : | 10.00% | 2033년 시장 규모 예측 : | 421억 2,000만 달러 |
기저 인슐린은 당뇨병 환자의 혈당 수치를 조절하기 위해 밤낮을 가리지 않고 인슐린을 안정적으로 분비하는 지속형 인슐린의 일종입니다. 일반적으로 인슐린 치료가 필요한 1형 당뇨병 또는 2형 당뇨병 환자에게 처방됩니다. 기저 인슐린은 식사 사이나 공복 시 혈당 수치를 안정적으로 유지하는 데 도움이 되며, 최적의 당뇨병 관리의 기반이 됩니다.
세계 기저 인슐린 시장은 전 세계 당뇨병 유병률 증가를 배경으로 눈부신 성장을 이루고 있습니다. 국제당뇨병연맹(IDF)에 따르면, 당뇨병을 앓고 있는 성인의 수는 2045년까지 7억 명에 달할 것으로 예측됩니다. 이러한 당뇨병 환자 수 증가는 당뇨병 관리에 필수적인 요소인 기저 인슐린에 대한 수요를 부추기고 있습니다.
시장 역학:
기저 인슐린 시장은 몇 가지 요인에 의해 주도되고 있습니다. 당뇨병, 특히 2형 당뇨병의 유병률 증가가 시장의 주요 성장 동력이 되고 있습니다. 앉아 있는 시간이 많은 생활, 부적절한 식습관, 비만과 같은 건강에 해로운 생활 습관이 전 세계 당뇨병 발병률 증가에 기여하고 있습니다. 그 결과, 기저 인슐린에 대한 수요가 크게 증가할 것으로 예측됩니다.
또한, 인슐린 치료 기술의 발전도 시장 성장을 뒷받침하고 있습니다. 약동학적 특성이 개선된 인슐린 아날로그의 개발로 인해, 기저 인슐린 요법의 유효성과 편의성이 크게 향상되었습니다. 이러한 발전 덕분에 혈당 조절이 개선되었으며, 저혈당의 위험도 줄어들었습니다.
예를 들어, 2023년 10월 23일, 임상 단계에 있는 바이오의약품 기업인 아도시아(Adocia)는 중국에 거점을 둔 제약사인 통화동보제약(Tonghua Dongbao Pharmaceutical Co. Ltd.)이 파트너임을 발표하고, 인슐린 리스프로와 인슐린 그랄긴을 포함한 제제 ‘BioChaperone Combo THDB0207”에 대해 실시된 3건의 임상시험에서 양호한 결과가 나왔음을 밝혔습니다. 이 세 가지 연구를 통해 BC Combo가 지속형 인슐린과 속효형 인슐린의 특성을 모두 갖춘 유용한 인슐린임이 입증되었습니다. 그 결과, 식후 및 공복 시 혈당 조절을 확실하게 유지할 수 있습니다.
그러나 기저 인슐린 시장의 성장을 저해할 가능성이 있는 몇 가지 제약 요인도 존재합니다. 인슐린 치료의 높은 비용이나 특정 지역의 의료 서비스 이용 제한 등이 그 장벽의 일부입니다. 또한, 인슐린의 제조 및 유통에 관한 엄격한 규제 요건 역시 시장 관계자들에게 과제가 되고 있습니다.
이러한 과제가 있음에도 불구하고, 기저 인슐린 시장에는 몇 가지 성장 기회가 존재합니다. 고령 인구 증가와 당뇨병 관리의 중요성에 대한 인식 제고가 시장 성장을 견인할 것으로 예측됩니다. 또한, 스마트 인슐린 투여 시스템의 개발과 당뇨병 관리에 디지털 기술을 접목하는 것은 시장 관계자들에게 새로운 가능성을 제시하고 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문에서 잠재적인 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 전 세계 기저 인슐린 시장의 주요 기업들에 대해서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략을 바탕으로 프로파일이 작성되었습니다.
- 본 조사에서 다루고 있는 주요 기업으로는 노보노르디스크, 사노피, 일라이 릴리 앤 컴퍼니, 바이오콘, 건 앤 리 파마슈티컬스, 톤호아 동바오 파마슈티컬, 유나이티드 래버러토리즈, 머크, 워크하트, 줄파르 디아베티스, 메드트로닉, 베타 바이오닉스, 지랜드 파마, 맨카인드, 펩트론, 덱스콤, 센소닉스, 메드트램 테크놀로지스, SOOIL 디벨롭먼트, 그리고 세마 테라퓨틱스가 포함됩니다.
- 본 보고서의 인사이트를 활용함으로써, 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계 기저 인슐린 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 기저 인슐린 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 기저 인슐린 시장 : 유형별, 2021-2033년
제5장 세계의 기저 인슐린 시장 : 투여 디바이스별, 2021-2033년
제6장 세계의 기저 인슐린 시장 : 적응증별, 2021-2033년
제7장 세계의 기저 인슐린 시장 : 연령층별, 2021-2033년
제8장 세계의 기저 인슐린 시장 : 유통 채널별, 2021-2033년
제9장 세계의 기저 인슐린 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 섹션
JHS 26.07.09Basal Insulin Market is estimated to be valued at USD 21.62 Bn in 2026 and is expected to reach USD 42.12 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 21.62 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.00% | 2033 Value Projection: | USD 42.12 Bn |
Basal insulin is a type of long-acting insulin that provides a steady release of insulin throughout the day and night to control blood sugar levels in individuals with diabetes. It is typically prescribed for individuals with type 1 diabetes or type 2 diabetes who require insulin therapy. Basal insulin helps maintain stable blood sugar levels between meals and during periods of fasting, providing a foundation for optimal diabetes management.
The global basal insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, the number of adults with diabetes is expected to reach 700 million by 2045. This rise in diabetes cases is fueling the demand for basal insulin, as it is an essential component of diabetes management.
Market Dynamics:
The basal insulin market is driven by several factors. The rising prevalence of diabetes, particularly type 2 diabetes, is a key driver for the market. Unhealthy lifestyle habits, such as sedentary behavior, poor diet, and obesity, are contributing to the increasing incidence of diabetes globally. As a result, the demand for basal insulin is expected to rise significantly.
In addition, advancements in insulin therapy technologies are also driving the market growth. The development of insulin analogs, which have improved pharmacokinetic properties, has significantly enhanced the efficacy and convenience of basal insulin therapy. These advancements have led to better glycemic control and reduced risks of hypoglycemia.
For instance, on October 23, 2023, Adocia, a biopharmaceutical company in the clinical stage, announced that Tonghua Dongbao Pharmaceutical Co. Ltd., a pharmaceutical company based in China, is its partner and has released positive results from three clinical studies conducted on the BioChaperone Combo THDB0207 formulation, which contains insulin lispro and insulin glargine. These three studies showed that BC Combo is a useful insulin that combines the qualities of both long-acting and rapid-acting insulin. As a result, it can guarantee glycemic control during the postprandial and fasting periods.
However, there are certain restraints that may hinder the growth of the basal insulin market. The high cost of insulin therapy and limited access to healthcare in certain regions are some of the barriers. Additionally, the stringent regulatory requirements for insulin production and distribution pose challenges for market players.
Despite these challenges, there are several opportunities for growth in the basal insulin market. The increasing geriatric population, as well as the growing awareness about the importance of diabetes management, are expected to drive the market growth. Furthermore, the development of smart insulin delivery systems and the integration of digital technologies in diabetes management present new avenues for market players to explore.
Key Features of the Study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- Key players in the global basal insulin market are profiled based on company highlights, product portfolio, key highlights, financial performance, and strategies
- Key companies covered in this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, and Semma Therapeutics
- Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
- The global basal insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal insulin market
Basal Insulin Market Segmentation:
- By Type (Revenue, USD Bn, 2021 - 2033)
- Glargine
- Detemir
- Degludec
- By Delivery Device (Revenue, USD Bn, 2021 - 2033)
- Syringes
- Pens
- Pumps
- Others (Inhalers, Patches)
- By Indication (Revenue, USD Bn, 2021 - 2033)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- By Age Group (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adults
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Basal Insulin Market:
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Basal Insulin Market, By Type
- Global Basal Insulin Market, By Delivery Device
- Global Basal Insulin Market, By Indication
- Global Basal Insulin Market, By Age Group
- Global Basal Insulin Market, By Distribution Channel
- Global Basal Insulin Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of diabetes, particularly type 2 diabetes
- Restraints
- High cost of insulin therapy
- Opportunities
- Increasing geriatric population
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Basal Insulin Market, By Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Detemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Degludec
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Basal Insulin Market, By Delivery Device, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Pumps
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Inhalers, Patches)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Basal Insulin Market, By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Global Basal Insulin Market, By Age Group, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Global Basal Insulin Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
9. Global Basal Insulin Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gan & Lee Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Tonghua Dongbao Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- United Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Wockhardt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Julphar Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beta Bionics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zealand Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- MannKind
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Peptron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Dexcom
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Senseonics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Medtrum Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SOOIL Development
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Semma Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
